A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Local Institution - 902, Odense

Local Institution - 903, Vejle

Local Institution - 402, Torino

Local Institution - 705, Marseille

Local Institution - 401, Milan

Local Institution - 605, Hamburg

Local Institution - 404, Brescia

Local Institution - 110, Winston-Salem

Local Institution - 508, Madrid

Local Institution - 501, Madrid

Local Institution - 506, Málaga

Local Institution - 108, Atlanta

Local Institution - 505, Pamplona

Local Institution - 701, Toulouse

Local Institution - 104, Tampa

Local Institution - 502, Salamanca

Local Institution - 702, Tours

Local Institution - 114, Nashville

Local Institution - 503, Santander

Local Institution - 403, Reggio Emilia

Local Institution - 115, Columbus

Local Institution - 704, Nantes

Local Institution - 507, Valencia

Local Institution - 113, Detroit

Local Institution - 106, Rochester

Local Institution - 703, Lille

Local Institution - 112, Chicago

Local Institution - 107, Chicago

Local Institution - 601, Heidelberg

Local Institution - 116, Houston

Local Institution - 604, Freiburg im Breisgau

Local Institution - 119, Denver

Local Institution - 602, München

Local Institution - 603, Würzburg

Swedish Cancer Institute, Seattle

Local Institution - 117, Boston

Local Institution - 101, Boston

Local Institution - 118, Boston

Hackensack University Medical Center, Hackensack

Local Institution - 201, Calgary

Local Institution - 205, Edmonton

Local Institution - 204, Halifax

Local Institution - 203, Toronto

Local Institution - 202, Montreal

Local Institution - 802, Brno

Local Institution - 801, Ostrava-Poruba

Local Institution - 803, Prague

Local Institution - 301, Athens

Local Institution - 504, Badalona